🏥 Prescribed at our clinic: Our endocrinologists evaluate, prescribe, and manage Ozempic for patients throughout Houston, Sugar Land, and Memorial City. Book a consultation →
Ozempic (semaglutide) is a once-weekly injectable medication made by Novo Nordisk. It belongs to a class called GLP-1 receptor agonists — medications that mimic the GLP-1 hormone your gut naturally releases after eating. Ozempic is FDA-approved for Type 2 diabetes and has strong evidence for reducing cardiovascular risk in patients with heart disease.
⚠️ Important: Ozempic is not FDA-approved for weight loss. Wegovy is the weight-loss-approved version of semaglutide. Using the right formulation matters for insurance coverage and dosing.
How Ozempic Works
Ozempic works through multiple mechanisms to control blood sugar:
Signals the pancreas to release insulin when blood sugar rises after meals — but only when glucose is elevated, reducing hypoglycemia risk.
Blocks glucagon (the hormone that raises blood sugar), preventing the liver from releasing excess glucose between meals.
Delays gastric emptying so glucose enters the bloodstream more slowly after meals, blunting post-meal glucose spikes.
Acts on the brain's appetite centers to reduce hunger and increase fullness after meals, leading to reduced calorie intake and weight loss as a side benefit.
Ozempic Dosing
Ozempic is started at a low dose and gradually increased to minimize gastrointestinal side effects:
- Starting dose: 0.25 mg once weekly for 4 weeks (to improve tolerability)
- Maintenance dose: 0.5 mg once weekly
- Maximum dose: 1.0 mg or 2.0 mg once weekly (for additional glucose lowering)
- Injected subcutaneously (under the skin) in the abdomen, thigh, or upper arm
- Can be taken any day of the week, with or without food
What Results Can You Expect?
- A1c reduction: Average 1.0–1.8% reduction in A1c (one of the strongest effects among diabetes medications)
- Weight loss: Average 5–7% of body weight lost in diabetes trials
- Cardiovascular protection: SUSTAIN-6 trial showed 26% reduction in major cardiovascular events in high-risk patients
- Blood pressure: Modest reductions in systolic blood pressure
Who Should Not Take Ozempic?
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- History of pancreatitis (use with caution — discuss with your doctor)
- Severe gastrointestinal disease (gastroparesis)
- Pregnancy or planned pregnancy
- Type 1 diabetes (not FDA-approved; insulin remains essential)
Ozempic vs. Wegovy vs. Mounjaro vs. Zepbound
Patients often ask how these medications compare. The key differences come down to the drug molecule, the FDA-approved indication, and the dose:
GLP-1 / GIP Medication Comparison
| Brand | Drug | Receptor | FDA Approval | Avg. Weight Loss |
|---|---|---|---|---|
| Ozempic | Semaglutide | GLP-1 | Type 2 Diabetes | ~5–7% |
| Wegovy | Semaglutide | GLP-1 | Weight Management | ~15% |
| Mounjaro | Tirzepatide | GIP + GLP-1 | Type 2 Diabetes | ~15–20% |
| Zepbound | Tirzepatide | GIP + GLP-1 | Weight Management | ~20–22% |
Frequently Asked Questions About Ozempic
What is Ozempic and what is it used for?
Ozempic (semaglutide) is a once-weekly injectable GLP-1 receptor agonist made by Novo Nordisk. It is FDA-approved for the management of Type 2 diabetes in adults. It lowers blood sugar by stimulating insulin release, slowing digestion, and reducing appetite. It is also proven to reduce the risk of major cardiovascular events (heart attack, stroke) in people with Type 2 diabetes and established heart disease. Ozempic is NOT FDA-approved for weight loss — Wegovy is the weight-loss-approved semaglutide.
How much weight do people lose on Ozempic?
In clinical trials for Type 2 diabetes, patients on Ozempic lost an average of 5–7% of body weight. This is meaningful but less than the weight loss seen with Wegovy (15%) or Zepbound/Mounjaro (20–22%), which are prescribed at higher doses specifically for obesity treatment. Weight loss varies significantly between individuals.
What are the most common side effects of Ozempic?
The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, constipation, and stomach discomfort. These are most prominent when starting the medication or increasing the dose, and typically improve over several weeks. Serious but rare risks include pancreatitis, gallbladder disease, and a theoretical risk of thyroid C-cell tumors (based on animal studies — the clinical significance in humans is unknown). Your endocrinologist will review your complete risk profile before prescribing.
What is the difference between Ozempic and Wegovy?
Both contain the same molecule — semaglutide — but at different doses. Ozempic's maximum dose is 2 mg weekly (approved for diabetes). Wegovy's maximum dose is 2.4 mg weekly (approved for weight management). Because of the higher dose, Wegovy produces significantly more weight loss on average (15% vs 5–7%). Ozempic is covered by diabetes insurance benefits; Wegovy uses obesity/weight management coverage.
Can I get Ozempic prescribed by an endocrinologist in Houston?
Yes. Our board-certified endocrinologists at Endocrine & Diabetes Plus Clinic of Houston prescribe and manage Ozempic and all GLP-1 medications. We serve patients in Sugar Land, Memorial City, and throughout greater Houston. A proper medical evaluation is required — we review your diabetes history, A1c, cardiovascular risk, and kidney function before prescribing.
Does insurance cover Ozempic?
Ozempic is generally well-covered by commercial insurance and Medicare Part D for patients with a Type 2 diabetes diagnosis. Prior authorization is commonly required. Coverage for weight loss (off-label use) is typically denied — Wegovy is the appropriate medication to request for weight management coverage.
Can Ozempic be used for Type 1 diabetes?
Ozempic is not FDA-approved for Type 1 diabetes. It can be used off-label in some cases under specialist supervision, but it does not replace insulin therapy and carries different risks in Type 1. Your endocrinologist can evaluate whether any GLP-1 therapy is appropriate for your specific situation.
Key Takeaways
- Ozempic (semaglutide) is FDA-approved for Type 2 diabetes — not weight loss
- Once-weekly injection with strong A1c-lowering and cardiovascular benefits
- Average weight loss 5–7% — meaningful, but less than Wegovy or tirzepatide
- Most side effects are GI-related and improve over time
- An endocrinologist ensures proper dosing, monitoring, and insurance coverage